DPT Laboratories To Integrate With Confab - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

DPT Laboratories To Integrate With Confab



The CDMOs DPT Laboratories, based in San Antonio, Texas, and Confab, based in Saint-Hubert, Quebec, have integrated under the leadership of Paul Johnson, group president and COO. Both DPT and Confab are owned by Renaissance Acquisition Holdings, a portfolio company of RoundTable Healthcare Partners, and represent its CDMO holdings.

The integration includes a rebranding and new logo for Confab, identifying it as a DPT company. A primary focus of the integration is for DPT’s sales and marketing team to introduce Confab’s experts in complex solid, semi-solid, and liquid dosage forms to new pharmaceutical industry clients, especially in the US market. The management teams for both companies will remain inplace, with Confab development and manufacturing continuing to operate under the direction of President and General Manager Nathalie Brisson. DPT has additional R&D and manufacturing facilities in Lakewood, New Jersey.

Source: DPT Laboratories

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
9%
Protecting the supply chain
39%
Expedited reviews of drug submissions
9%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here